Prospective Study Evaluating Dry Eye in Patients Operated on for Ametropia by LASIK Surgery and Treated With REPADROP - Trial NCT04654455
Access comprehensive clinical trial information for NCT04654455 through Pure Global AI's free database. This phase not specified trial is sponsored by Hospices Civils de Lyon and is currently Completed. The study focuses on Ametropia. Target enrollment is 10 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Describe the evolution of dry eye between 1 month and 3 months post-LASIK
Observational
other
Sponsor & Location
Hospices Civils de Lyon
Timeline & Enrollment
N/A
Mar 09, 2021
Nov 02, 2021
Primary Outcome
Variation in OSDI (Ocular Surface Disease Index) score
Summary
LASIK is a refractive surgery technique widely used in France. Postoperatively, the classic
 treatment after LASIK consists of instilling drops to reduce dry eyes. REPADROP® is an
 innovative eye drops stimulating corneal innervation. To date no study has quantified the
 improvement in dry eye syndrome and thus the quality of life of patients using REPADROP®.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04654455
Non-Device Trial